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Abstract 26 
Antimicrobial Resistance (AMR) is a major threat to human, animal health and 27 
environment worldwide. For human, transmission occurred through a variety of routes both in 28 
health care settings and community. In animals, AMR was reported in livestock, pets and wildlife; 29 
transmission of AMR can be zoonotic with the probably most important route being food-30 
borne transmission. The Indian Ocean Commission (IOC), composed of Comoros, 31 
Madagascar, Mauritius, Reunion (France) and Seychelles recognized the surveillance of 32 
AMR in both animal and human as a main public health priority for the region. Mayotte, 33 
French overseas territory, located in Comoros archipelago, was also included in this review. 34 
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This review summarized our best epidemiological knowledge regarding AMR in Indian 35 
Ocean. We documented the prevalence, phenotypic and genotypic profiles of prone to 36 
resistance Gram-positive and Gram-negative bacteria both in animals and humans. Our 37 
review clearly pointed out Extended-Spectrum β-Lactamase and Carbapenemase producing 38 
Enterobacteriaceae as main human and animal health issue in IOC. However, publications on 39 
AMR are scarce, particularly in Comoros, Mayotte and Seychelles. Thus, research and 40 
surveillance priorities were recommended i) estimating the volume of antimicrobial drugs 41 
used in livestock and human medicine in the different territories (mainly Third Generation 42 
Cephalosporin (3GC); ii) developing a “One Health” surveillance approach with 43 
epidemiological indicators as zoonotic foodborne pathogen (i.e. couple Escherichia Coli-44 
resistance to 3GC/ Carbapenems); iii) screening travelers with a history of hospitalization and 45 
consumption of antibiotic drug returning from at risk areas (e.g. mcr-1 transmission with 46 
China or hajj pilgrims) allowing an early warning detection of the emergence for quick 47 
control measures implementation in IOC. 48 
 49 
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 53 
Introduction 54 
Increasing global Antimicrobial Resistance (AMR) is a major threat to human and animal 55 
endangering decades of improvements in health care outcomes. It endangers modern 56 
human and veterinary medicine and undermines food safety (FAO, 2016).  57 
In humans, the global burden of AMR is longer duration of illness, higher lethality, 58 
increasing costs of treatment, and inability to cure infected patient (Laxminarayan et al., 59 
2013). In animals, antibiotic drugs use in terrestrial and aquatic animals maintains food 60 
safety, animal welfare, and protect livelihoods (Pagel and Gautier, 2012).  61 
Transmission of AMR to human can be zoonotic taking place through a variety of routes 62 
where the food-borne route is probably the most important (Wegener, 2012). Direct 63 
transmission also occurs for specific bacteria species (e.g. methicillin-resistant 64 
Staphylococcus aureus). 65 
The Indian Ocean Commission (IOC) is composed of five countries: Comoros, 66 
Madagascar, Mauritius, Reunion (France) and Seychelles. Mayotte, French overseas 67 
territory located in Comoros archipelago was also included in the study. In 2015, the IOC 68 
identified AMR surveillance in both animal and human as a main priority for territories 69 
(COI, 2015). However, AMR burden is not well evaluated but epidemiological trends in 70 
IOC should be identified.  71 
Our systematic review objective was summarizing epidemiological knowledge and trends 72 
of AMR in prone-to-multidrug resistance bacteria species (Magiorakos et al., 2012), faecal-73 
oral and foodborne bacteria in human and animals in IOC. We documented the prevalence, 74 
phenotypic and genotypic profiles of resistance of the selected bacteria in i) Gram-positive 75 
and ii) Gram-negative bacteria. 76 
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 77 
Material and methods 78 
The study performed from January to March 2017 included articles and conference abstracts 79 
published from 1990 to December 2016. Bacteria species included in the different searches 80 
were those prone to develop multidrug resistance as defined by Magiorakos et al. (2012) (i.e. 81 
Staphylococcus aureus, Enterococcus spp., Pseudomonas aeruginosa, Acinetobacter spp. and 82 
the genus Enterobacteriaceae), faecal-oral and foodborne bacterial species (Salmonella spp., 83 
Campylobacter spp. and Shigella spp.). We used available articles obtained through match 84 
searches using Google Scholar (http://scholar.google.com), PubMed 85 
(https://www.ncbi.nlm.nih.gov/pubmed) and Web of Knowledge 86 
(http://apps.webofknowledge.com/). Relevant information was obtained for phenotypic and 87 
genotypic profiles of resistance in selected bacteria using its name combined with related 88 
terms (resistance, antimicrobial, antibiotic, Comoros, Seychelles, Reunion Island, 89 
Madagascar, Mayotte, Indian Ocean, epidemiology). Included publications were those 90 
documenting the prevalence, phenotypic and genotypic profiles of resistances of selected 91 
bacteria, others were excluded.  92 
 93 
Results and discussion 94 
A total of 42 articles were considered relevant for the review.  95 
 96 
a. Gram-positive bacteria 97 
Staphylococcus aureus  98 
Staphylococcus aureus is one of the most common causes of nosocomial and community 99 
infections (von Eiff et al., 2001). Since 1960s, methicillin-resistant S. aureus (MRSA) were 100 
isolated (McCaig et al., 2006) and became a major nosocomial pathogen (Mulligan et al., 101 
1993).  102 
In Madagascar, MRSA was increasing from 2001 to 2014 as observed in table 1 with rising 103 
rate of resistance to oxacillin and cefoxitin. MRSA nasal carriage in community was observed 104 
with a prevalence of 14.8% in 2011 (Rasamiravaka et al., 2013, 2016). Overall resistances 105 
were higher for widely available drugs (Randrianirina et al., 2007a). Moreover, 9.0% of 106 
veterinary students were asymptomatic MRSA carriers (Rasamiravaka et al., 2016). 107 
Increasing rate of resistance to gentamicin (42.9%) and vancomycin (7.1%) was observed in 108 
MRSA isolates (Rasamiravaka et al., 2016). Nonetheless, vancomycin and tigecycline are the 109 
last drugs demonstrating therapeutic efficacy for MRSA and are compromised by the reduced 110 
susceptibility in S. aureus (Hu et al., 2016). Phenotypic resistance observed in Madagascar 111 
was of concern (Rasamiravaka et al., 2016), confirmation by a antimicrobial reference 112 
laboratory for genotyping should be considered.  113 
In Mauritius, in May 2010, among all S. aureus isolated in hospitalized patients 114 
infections 37.8% were MRSA (Issack et al., 2011) and 39% were MRSA in July 2014 (Issack, 115 
2016a). All S. aureus tested were susceptible to vancomycin (Issack et al., 2011; Issack, 116 
2016a).  117 
In Reunion, MRSA increased from 16.0% in 1997 to 23.0% in 2000 and decreased to 118 
less than 15.0% in 2006/07 (Belmonte et al., 2008). S. aureus rate of resistance to all 119 
antibiotic drugs decreased from 1997 to 2007, with the exception of the fusidic acid (16.0% in 120 
4 
 
2007). Since 1998, S. aureus susceptibility profile changed tending to be more resistant to 121 
aminoglycosides and quinolones (Belmonte et al., 2008). 122 
In the other territories, literature remains absent and no publication was found 123 
regarding prevalence and antibiotic resistance profiles of S. aureus in humans, livestock and 124 
pets. 125 
MRSA epidemiological trends should be better addressed in Comoros, Mayotte, Reunion and 126 
Seychelles. Rates of resistances for widely available oral agents observed in Madagascar 127 
could point out a drug overuse in this territory as well as in Mauritius.   128 
Burden of MRSA in livestock and pets should be addressed particularly as they can directly 129 
contaminate veterinary, breeders or other animals (Moodley et al., 2008).  130 
 131 
Enterococcus spp. 132 
Enterococcus spp. are opportunistic bacteria often involved in nosocomial infections, mainly 133 
urinary tract infections, endocarditis, wounds and bacteremia (Murray, 2000). Discovered end 134 
of 1980’s (Woodford et al., 1995), vancomycin-resistant enterococci (VRE) represents a 135 
major problem in healthcare settings worldwide. 136 
In Madagascar, in 2006-2008, rate of resistance to vancomycin in Enterococcus spp. 137 
was 3.3% and was high for lincomycin (90.0%) (Randrianirina et al., 2010). In 2011-2013, 138 
one E. faecalis resistant to vancomycin (5.6%) was isolated during an uropathogenic survey 139 
(Rasamiravaka et al., 2015). 140 
In Mauritius, in May 2010 and July 2014, all Enterococcus spp. isolated in 141 
hospitalized patients were susceptible to vancomycin (Issack et al., 2011; Issack, 2016a). 142 
In Reunion, Picot et al. (2010) did not detect any VRE in 2005 (Picot et al., 2010). In 143 
other territories, no publication was found for both humans and animals. 144 
Thus, epidemiological situation of VRE is not clear in IOC but doesn’t seem being a 145 
main issue both in animals and humans. Identifying drug uses in livestock remains necessary 146 
as glycopeptide (e.g avoparcin) use in livestock was correlated with VRE incidence in human 147 
populations (van den Bogaard and Stobberingh, 2000).  148 
 149 
b. Gram-negative bacteria 150 
Pseudomonas aeruginosa 151 
Pseudomonas aeruginosa is an opportunistic pathogen causing nosocomial infections 152 
(Zhanel et al., 2010). Some strains have been found to be resistant to nearly all antibiotics 153 
(Ventola, 2015).  154 
In Madagascar, in 2006-2008, P. aeruginosa isolates showed a moderate resistance to 155 
penicillin (piperacillin 12.8% and ticarcillin 31.9%) but were susceptible to ceftazidime and 156 
imipenem (Randrianirina et al., 2010).  157 
In Mauritius, in May 2010, P. aeruginosa isolated in hospitalized patients showed 158 
high rate of resistance to antibiotic tested with 51.5% to aminoglycosides (52% gentamicin 159 
and 51% amikacin), 47% for ceftazidime, 73% for ciprofloxacin and 40% for meropenem 160 
(Issack et al., 2011). In July 2014, a similar survey pointed a decrease of all resistance tested 161 
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(42% for gentamicin, 29% for amikacin, 30% for ceftazidime, 47% for ciprofloxacin and 27% 162 
for meropenem) (Issack, 2016a) 163 
In Reunion, rates of resistance to imipenem increased from 1997 to 2005 (5.9% to 164 
6.1%) (Picot et al., 2010). Outbreaks of P. aeruginosa were reported in a neonatal care unit 165 
(Gérardin et al., 2006; Naze et al., 2010) but susceptibility testing of strain was not performed. 166 
In Reunion, between 2010-2012, OXA-221 was identified in P. aeruginosa associated with β-167 
lactamases and carbapenemase production (Jeannot et al., 2012). The Extended-spectrum β-168 
lactamase OXA-145 was describe in 2011 in P. aeruginosa and conferred resistance to 3GC 169 
and monolactams (Hocquet et al., 2011). 170 
Trends regarding P. aeruginosa in IOC are not clear but acquisition of new gene of 171 
resistance to β-lactams is of concern. Rate of resistance to carbapenems identified in 172 
Mauritius are high even if decreasing. Identifying its burden in nosocomial infection is needed 173 
as well as aminoglycoside resistance. Recommended treatment for pseudomonas infection 174 
usually includes β-lactams and aminoglycosides. 175 
 176 
Acinetobacter spp. 177 
Acinetobacter baumannii is a troublesome pathogens for health care institutions, its 178 
ability to acquire resistance determinants, is making it threatening the current antibiotic era 179 
(Peleg et al., 2008).  180 
In Madagascar, in 2006-2008, a prevalence of A. baumannii of 8.8% was identified in 181 
infections diagnosed at hospital, the resistance to ceftazidime (62.0%) and imipenem was high 182 
(45.7%) (Randrianirina et al., 2010).Among strains collected between 2006-2009 92.5% were 183 
resistant to imipenem and 94.3% to ceftazidime (Andriamanantena et al., 2010). No resistance 184 
to carbapenems was reported among ten uropathogenic isolates in community (2011-2013) 185 
(Rasamiravaka et al., 2015) but this restricted sample could not reflect the epidemiological 186 
situation. The dissemination of multidrug-resistant OXA-23-producing A. baumannii in 187 
hospitals of Antananarivo (Andriamanantena et al., 2010) could emphasize issues regarding 188 
failures of infection control in hospitals (Randrianirina et al., 2010).   189 
In Mauritius, in May 2010, Acinetobacter spp. isolated in hospitalized patients showed 190 
high rate of resistance to antibiotic tested with 86% for gentamicin and 50% for amikacin 191 
(both aminoglycosides), 95% for cefotaxime, 85% for ciprofloxacin and 68% for Meropenem 192 
(Issack et al., 2011). In July 2014, a similar survey pointed a decreasing rate of resistance for 193 
gentamicin, cefotaxime and ciprofloxacin (respectively 79%, 94% and 82%) and increasing 194 
for amikacin (58%) and meropenem (74%) (Issack, 2016a). 195 
In Reunion, from 1997-2005, A. baumannii rate of resistance decreased to all 196 
antibiotic tested (e.g. ceftazidime (74.3% to 68.1%), imipenem (12.9% to 8.3%), and 197 
ciprofloxacin (72.9% to 59.7%) (Picot et al., 2010). In 2006, an outbreak of multi-resistant A. 198 
baumannii phenotype 5 occurred at the hospital, strains were resistant to all β-lactams 199 
(Belmonte et al., 2010). A wide variety of A. baumannii sequence types was identified at the 200 
hospital and could be related to community-acquired infections; one isolate carrying the 201 
blaOXA-23
-
 gene was identified (Pailhoriès et al., 2015).  202 
In Comoros, the blaOXA-23
-
 gene in A. baumannii was identified in 2011 (Bonnin et al., 203 
2013).  204 
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Pets can be reservoir of A. baumannii (Belmonte et al., 2014). In Reunion the 205 
prevalence in pets was 8.5% but no isolates were resistant to carbapenems (Pailhoriès et al., 206 
2015). In cattle, the first case of OXA-24
- 
producing A. baumannii was recently identified 207 
(Pailhoriès et al., 2016). 208 
Resistance to carbapenems in A. baumannii was observed in Comoros, Madagascar, Reunion 209 
and Mauritius. It is of concern for IOC as A. baumannii have an affinity with vulnerable 210 
patients (Gootz and Marra, 2008). Producing-carbapenemase A. baumannii, with the 211 
dissemination of OXA-23 enzymes, should be thoroughly monitored, keeping in mind the 212 
possible clonal spread of multi-resistant strains in hospital, community and pets.  213 
 214 
Enterobacteriaceae 215 
β-lactamases production are the primary cause of resistance among members of the family 216 
Enterobacteriaceae. In recent years, β-Lactamases have extensively diversified in response to 217 
clinical use of β-Lactams (Liakopoulos et al., 2016).  218 
i) Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae (ESBLE) 219 
ESBLE confer resistance to β-lactam antibiotics except cephamycins and carbapenems and 220 
are inhibited by clavulanic acid (Kliebe et al., 1985).  221 
ESBLE was first isolated in Madagascar between 2004-2006 in urinary tract infections 222 
(Randrianirina et al., 2007b) as observed in table 2. High fecal carriage of ESBLE was 223 
identified in both hospital and community with prevalence of 21.3% in two hospitals from 224 
2006-2008 (Randrianirina et al., 2010), 21.2% in a pediatric hospital in 2008 (Andriatahina et 225 
al., 2010) and 10.1% in community in 2009 (Herindrainy et al., 2011). Between 2013 and 226 
2014, 18.5% of rectal colonization was estimated among pregnant women at delivery 227 
(Chereau et al., 2015). Another study (2015) pointed out 7.1% of Enterobacteriaceae nasal 228 
carriage resistance to Third Generation Cephalosporin (3GC) in patients at admission 229 
(Micheel et al., 2015). A study conducted from 2012 to 2013 pointed out the burden of 230 
ESBLE in early neonatal infection (12.9%); infections were treated with expanded spectrum 231 
cephalosporins due to the lack of carbapenems, and resulted in a high lethality (45 %) (Naas 232 
et al., 2016). In Madagascar, ESBLE mostly belong to the CTX-M-15 type (Rakotonirina et 233 
al., 2013; Naas et al., 2016), widely distributed worldwide (Coque et al., 2008). 234 
In Mauritius, in 2005, rate of resistance to 3GC in Enterobacteriaceae from urine of 235 
patients with presumed community-acquired infection was about 9.0% for cefotaxime and 236 
14.7% for cefixime (table 2). Isolates also showed high rates of resistance to fluoroquinolones 237 
(26.4% to ciprofloxacin) (Issack et al., 2007). Between 2010 and 2014, an increase of 238 
resistance in Enterobacteriaceae isolated in hospitalized patients was observed (46.7% to 239 
50.7% for cefotaxime and 39.2% to 56.1% for ciprofloxacin) (Issack et al., 2011; Issack, 240 
2016a). 241 
In Reunion, prevalence of ESBLE was increasing at hospital with 2.0% in 1997 and 242 
5.8% in 2007 (Belmonte et al., 2010). Broad-spectrum antibiotics use in hospitals was likely 243 
correlated with this evolution (Belmonte et al., 2010). In 2013, main ESBLE involved in 244 
infections where Klebsiella pneumoniae (38.0%), Escherichia coli (37.0%) and Enterobacter 245 
cloacae (24.0%) with 75.0% of the CTX-M-15 type (Robin et al., 2014).  246 
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A prevalence of 14.5% ESBLE was estimated among dogs and cats from veterinary 247 
clinics of Reunion Island (Belmonte et al., 2013). 248 
In livestock from Comoros, Madagascar, Mauritius and Mayotte, overall 22.7% of 249 
livestock sampled were ESBLE carriers. The highest prevalence was observed among pigs 250 
(42.0%) and poultry (26%); Main contaminated farms were located in Madagascar (40.5%), 251 
Mayotte (26.9%) followed by Mauritius (13.5%) and Comoros (6.7%) (Miltgen et al., 2014). 252 
No publication was found for Seychelles but prevalence of ESBLE (mainly represented by E. 253 
coli, K. pneumoniae and E. cloacae) in IOC seems increasing both in humans and animals. 254 
Broad-spectrum antibiotics overuse is likely correlated with this evolution (Belmonte et al., 255 
2010).  256 
 257 
ii) Carbapenemase producing Enterobacteriaceae (CPE) 258 
In Madagascar first CPE was reported in a community survey of uropathogens implemented 259 
in 2011-2013 (Rasamiravaka et al., 2015). Imipenem rate of resistance was 40.0% for K. 260 
pneumoniae, 15.0% for E. cloacae and 2.3% for E. coli (Rasamiravaka et al., 2015). The 261 
reduced sample size for this study could not reflect global resistances patterns.  262 
In Mauritius, rate of resistance to meropenem in Enterobacteriacae increased from 0.51% in 263 
2010 to 5.32% in 2014 among hospitalized patients (Issack et al., 2011; Issack, 2016a).  264 
In Reunion, in 2007, resistance to imipenem in Enterobactericeae was low (1 to 2 cases by 265 
year) (Belmonte et al., 2008).  266 
First detection of New Delhi Methallo-β-Lactamase-1 (NDM-1) gene in K. pneumoniae in 267 
IOC occurred in a Mauritius patient in 2009 (Poirel et al., 2012), in 2011 in Reunion (Cabanes 268 
et al., 2012), in 2013-2014 in Madagascar (Chereau et al., 2015).  269 
In Mayotte, an outbreak of CPE involving E. cloacae of IMI-1 type occurred at the hospital 270 
(Miltgen al., 2016). First investigations tend to highlight a community source of 271 
contamination but further investigations should confirm it (Miltgen et al., 2016).  272 
In animal, no publication was found regarding CPE.  273 
CPE are endangering the ability to cure infectious diseases. NDM-1 fast propagation 274 
in IOC is pointing the need of AMR surveillance and alert system. Mauritius seems 275 
particularly affected by CPE, their spread could constitute an issue for other territories as few 276 
therapeutic alternatives are available to treat infected patients. 277 
 278 
iii) Foodborne and faecal-oral origin Enterobacteriaceae   279 
1. Non-typhoidal Salmonella spp. 280 
Salmonella is a major foodborne pathogen found worldwide. Most human 281 
salmonellosis is associated with eating contaminated raw or undercooked chicken, eggs, pork 282 
and contaminated water.  283 
 284 
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In Madagascar, in 2008-2009, Salmonella spp. rate of resistance in community-285 
children was low for 3GC (1.2% for ceftazidime and cefotaxime), absent for quinolones and 286 
moderated for ampicillin (35.7%) and ticarcillin (35.7%) (Randrianirina et al., 2014). 287 
In Mauritius, in 2009, Salmonella enterica serovar Enteritidis was isolated in humans 288 
without resistance identified for all antibiotic tested; transmission by chicken consumption 289 
was suspected (Issack et al., 2014). In 2014, Salmonella spp. isolated in stools of patients with 290 
gastroenteritis were all sensitive to Ampicillin and Ciprofloxacin and presented low resistance 291 
to Trimethoprim-sulfamethoxazole (2%) and Nalidixic Acid (1%) (Issack, 2016b). 292 
In Reunion, between 2007-2009, rates of resistance among Salmonella spp. isolated in 293 
broiler chicken flocks were of 38.3% to streptomycin, 31.8% to tetracycline and 16.8% to 294 
ampicillin (Henry et al., 2013) but no resistance to 3GC was identified. S. Hadar displayed 295 
reduced susceptibility to fluoroquinolones (80.8% to enrofloxacin) (Henry et al., 2013). 296 
 297 
In Comoros, no resistance in Salmonella spp. was identified between 1987-1988 (Petat 298 
et al., 1990). 299 
 300 
Publications regarding AMR among Salmonella spp. are scarce in IOC. Resistances to 301 
quinolones in Salmonella spp. seems appearing in Reunion, probably do to its overuse, but 302 
not in Mauritius.  303 
 304 
2. Campylobacter spp. 305 
Campylobacter spp. can cause both gastroenteritis and extra-intestinal disease. C. 306 
jejuni and C. coli are the most often isolated from patients with diarrhea as confirmed in 307 
Madagascar in 2010-2012 (70.1% and 23.6% respectively) (Randremanana et al., 2014). Main 308 
infection source in humans is undercooked chicken, raw or unpasteurized milk, and cross-309 
contamination from the environment (Humphrey et al., 2007). 310 
In Madagascar, rate of resistance in Campylobacter spp. was moderate in community 311 
children in 2008-2009, with overall resistance of 24.8% for amoxicillin, 2.2% for 312 
ciprofloxacin, 1.8% for erythromycin and 1.1% for tetracycline (Randrianirina et al., 2014). 313 
Rate of resistance was higher for C. coli (Randrianirina et al., 2014).  314 
In animals, Campylobacter spp. collected in 2005-2006 from chicken neck‐skin in 315 
Madagascar presented 35.8% of resistance to ampicillin, 18.3% to erythromycin, 5.5% to 316 
ciprofloxacin and 3.7% to nalidixic acid (Garin et al., 2012).  317 
In Mauritius, in 2014, Campylobacter spp. isolated in gastroenteritis cases presented 318 
high resistance to Quinolones with 51% of resistance to ciprofloxacin and 4% to erythromycin 319 
(Issack, 2016b). High quinolone resistance in Campylobacter spp. is probably due to 320 
antibiotic overuse in veterinary medicine (Issack, 2016b). 321 
Publications regarding AMR among Campylobacter spp. are scarce in IOC 322 
particularly in animals. Resistance to quinolones in Mauritius could be due to its overuse in 323 
poultry industry (Issack, 2016b).  324 
 325 
3. Shigella spp. 326 
Shigella spp. is responsible for dysentery predominating in developing countries 327 
(Kahsay and Muthupandian, 2016).  328 
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In Madagascar, in 1988-1989, resistances in S. dysenteriae started being observed 329 
(Cassel-Béraud et al., 1990). In 2008-2009, rate of resistance in community children were 330 
high for widely used drugs (e.g. 79.9% for trimethoprim-sulfamethoxazole, 62.8% for 331 
amoxicillin, 62.2% for ticarcillin) but no resistance for ciprofloxacin was reported 332 
(Randrianirina et al., 2014).  333 
In Comoros, Shigella spp. isolated between 1987-1988 did not exhibit significant 334 
resistances (Petat et al., 1990). 335 
Few up-to-date publications regarding AMR in Shigella spp. were found. 336 
 337 
Perspectives 338 
One main challenge regarding this review was the data collection and comparison of 339 
AMR patterns between territories in the diversity of study designs (diagnosis isolates vs. 340 
systematic detection), antibiogram panels, over different periods of time and targeting various 341 
bacteria species. Thus, results should be interpreted with caution but this attempt of review 342 
was not performed before and confirmed that AMR is threatening IOC. Main issue identified 343 
for IOC was ESBL and CPE which is in agreement with their increase worldwide over the 344 
past decade (Cantón et al., 2012). 345 
Literature was limited in Comoros, Mayotte and Seychelles confirming needs to 346 
develop AMR surveillance and research in these territories and scarce for bacterial species: 347 
Enterococcus spp., Pseudomonas aeruginosa, Salmonella spp., Campylobacter spp. and 348 
Shigella spp.  349 
In IOC, the SEGA-One Health network was created in 2009 with the objective of 350 
monitoring outbreak-prone infections (Solet et al., 2014). It aims to develop a surveillance of 351 
AMR in human and animals but disparity of resources between territories and between animal 352 
and human health could be a brake in the establishment of such a system.  353 
Thus, priorities should be established: 354 
 i) A direct relationship between antibiotic consumption, emergence and dissemination 355 
of AMR was demonstrated (The antibiotic alarm, 2013). Estimating the volume of 356 
antimicrobial drugs used, types and access (e.g. over-the-counter) is an essential step for IOC. 357 
The overuse of 3GC could have driven to selection pressures on bacterial community in both 358 
animals and humans observed (i.e. ESBLE and CPE in hospitals with carbapenems use). 359 
Drugs monitoring could help predicting risks of emergence in territories (Van Boeckel et al., 360 
2015). Research on drug uses and habits in community, by practitioners and in livestock 361 
should be explored to adapt control measures.  362 
ii) Integrated AMR One health approach including human, animal and environment in 363 
both surveillance and research is clearly needed (e.g. MRSA in veterinarians, A. baumannii in 364 
pets, humans and livestock, ESBLE in livestock and humans). Using standardized indicators 365 
(antibiotic drugs-bacteria species couple) for surveillance of AMR patterns across health care 366 
settings, countries and host species is essential. One relevant epidemiological indicator, for 367 
both animal and human, could be E. Coli AMR, particularly 3GC and carbapenems. 368 
Surveillance should be accompanied by further investigations regarding genetic support of 369 
resistance between hosts for source of contamination and dynamics of propagation between 370 
reservoirs identification (human, animal and environment). 371 
10 
 
iii) Spread of NDM-1-Producing Enterobacteriaceae in IOC confirms needs for 372 
strengthening the early warning surveillance system of AMR emergences. The region is 373 
connected to hotspots of AMR as Asia (12.0% of traffic) characterized by high AMR 374 
prevalence in community (e.g. ESBL in China (Quan et al., 2017), important antibiotic 375 
consumption (Van Boeckel et al., 2014), and emergence of new AMR profiles (e.g. NDM-1, 376 
mcr-1) (Liu et al., 2016)). Screening of travelers, returning from at risk AMR areas, with a 377 
history of hospitalization and consumption of antibiotic drugs abroad has been recently 378 
proposed (Armand-Lefevre et al., 2017) and could be relevant for an early emergence 379 
detection. However, screening is costly, thus, initiating reflection regarding pooling 380 
laboratory resources is essential.  381 
Our article is the first attempt summarizing knowledge regarding AMR in both animal and 382 
human health sectors in IOC. This review clearly points out research and surveillance gaps 383 
and constitutes a tool for future activities to lead.  384 
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 Table 1. Evolution of antibiotic resistance of S. aureus from 2001 to 2014 in Indian Ocean 680 
Commission 681 
 682 
Country Population Year Study design Sample type 
Isolates 
number 
OXA/CEF PEN ERY LIN SXT GEN Reference 
Madagascar Com 2001-2005 
Laboratory 
surveillance 
Pus, genital, 
urine, 
respiratory 
68 6.5% 87.9% 14.6% 6.1% 16.8% 1.9% 
(Randrianirina et 
al., 2007a)  
Madagascar Hosp 2001-2005 
Laboratory 
surveillance 
Surgical 
wounds, 
pus, 
hemoculture 
506 4.4% 91.2% 10.3% 7.3% 13.2% 0.0% 
(Randrianirina et 
al., 2007a)  
Reunion Hosp 2007 
Laboratory 
surveillance 
Unknown 
(diagnostic 
specimen) 
-- 13% 85.0% 18.0% 11% 0.4% 0.8% 
(Belmonte et al., 
2008) 
Madagascar Hosp 2010 
Laboratory 
surveillance 
Surgical 
wounds, 
pus, burn, 
urine, 
respiratory 
103 13.6% 92.2% 19.4% 5,8 NI 3.9% 
(Randrianirina et 
al., 2010)  
Mauritius Hosp 2010 
Laboratory 
surveillance 
Unknown 
(diagnostic 
specimen) 
127 37.8% 95.3% 27.6% NI NI NI (Issack et al., 2011) 
Madagascar Com 2011 
Cross-
sectional 
study 
Nasal swabs 45 38.8% 100.0%* 66.7%* 31.1%* 68.9%* 4.4%* 
(Rasamiravaka et 
al., 2013)  
Madagascar Com 2011-2013 
Laboratory 
surveillance 
Urine 48 8.3% 75.0% NI NI 58.3% NI 
(Rasamiravaka et 
al., 2015)  
Madagascar 
Com 
(veterinarian) 
2013-2014 
Cross-
sectional 
study 
Nasal swabs 30 46.7% 100% 60.0% NI 76.7% 20% 
(Rasamiravaka et 
al., 2016) 
Madagascar 
Com 
(veterinarian) 
2013-2014 
Cross-
sectional 
study 
Nasal swabs 14 100.0%* 100%* 64.3%* NI 71.4%* 42.9%* 
(Rasamiravaka et 
al., 2016)  
Mauritius Hosp 2014 
Laboratory 
surveillance 
Blood 
culture, pus, 
burn, urine, 
swab, 
respiratory 
intravascular 
catheter  
140 39.0% NI 31.0% NI NI NI (Issack, 2016a) 
OXA: oxacillin/CEF: cefoxitin, PEN: penicillin, ERY: erythromycin, LIN: lincomycin, SXT: trimethoprim sulfamethoxazole, GEN: 683 
gentamicin; NI: not identified; * Resistance in MRSA strains 684 
 685 
Table 2. Evolution of antibiotic resistance of Enterobacteriaceae from 2004 to 2013 in Indian 686 
Ocean Commission  687 
 688 
Country/ 
Year 
Population 
Study 
design 
Sample type 
Isolates 
number 
 
ESBL carriers/ 
individuals 
tested 
ESBLE/ 
Enterobacteriaceae 
tested 
AMX AMC 
CAZ/ 
CEF 
GEN NAL CIP SXT 
Bacterial 
Species 
References 
17 
 
Madagascar 
2004-2006 
Com 
Laboratory 
surveillance 
urine 775 NI 3.8% 76.4% 15.6% 4.0%/ - 9.2% 24.5% 15.4% 64.8% 
E. Coli, K 
Pneumoniae, 
Proteus spp., 
Enterobacter 
spp., 
Citrobacter 
spp. 
(R
andrianirina 
et al., 2007b) 
Mauritius 
2005 
Com 
Laboratory 
surveillance 
Urine 224 NI 12.9% NI 1,60% 
- / 
9.0% 
9.9% 34.0% 26.4% 49.5% 
E. Coli, 
Klebsiella 
spp., Proteus 
spp. 
(Issack et al., 
2007) 
Reunion 
2006-2007 
Hosp 
Laboratory 
surveillance 
Unknown 
(diagnostic 
specimen) 
240* NI 5.8% NI NI NI 67.0% NI 74.0% 75.0% 
E. Coli, E. 
Cloacae, K. 
Pneumoniae 
(Belmonte et 
al., 2010)  
Madagascar 
2006-2008 
Hosp 
Laboratory 
surveillance 
Surgical 
wounds, 
pus, burn, 
urine, 
respiratory  
249 NI 21.3% 91.0% 69.0% 
26,0% 
/26.0% 
31.0% 52.0% 41.0% 71.0% 
E. Coli, K. 
Pneumoniae, 
Proteus spp., 
Enterobacter 
spp., 
Citrobacter 
spp. 
(Randrianirina 
et al., 2010)  
Madagascar 
2008 
Hosp 
Cohort 
study 
Stool 30* 57,10% NI 100.0% 100.0% 86.2% 91.4% 62.0% 50.0% 96.5% 
E. Coli, K. 
Pneumoniae 
(A
ndriatahina et 
al., 2010) 
Madagascar 
2008 
Com 
Cohort 
study 
Stool 58* 22,10% NI 100.0% 100.0% 90.0% 76.7% 63.3% 46.7% 93.3% 
E. Coli, K. 
Pneumoniae 
(Andriatahina 
et al., 2010)  
Madagascar 
2008-2009 
Com 
Cross-
sectional 
study 
Stool 195 NI 3.1% 82.%1 1.0% 
1.5% 
/3.1% 
1.0% 10.8% 3.1% 84.6% E. Coli 
(Randrianirina 
et al., 2014)  
Madagascar 
2009 
Com 
Cross-
sectional 
study 
Stool 53* NI NI 100.0% 98.0% NI NI 68.6% 60.8% 90.2% 
E. Coli, K. 
Pneumoniae, 
Enterobacter 
spp., 
Citrobacter 
spp. 
(Herindrainy 
et al., 2011)  
Mauritius 
2010 
Hosp 
Laboratory 
surveillance 
Unknown 
(diagnostic 
specimen) 
195 NI NI NI NI 46.7% 50.6% NI 39.2% NI 
E. Coli, K. 
Pneumoniae 
(Issack et al., 
2011) 
Madagascar 
2011-2013 
Com 
Laboratory 
surveillance 
Urine 224* NI 33.0% 80.8% 58.0% 
30.4%- 
30.4% 
NI NI NI 69.2% 
E. Coli, 
Citrobacter 
spp., K 
pneumoniae, 
Proteus spp., 
Serratia spp. 
(Rasamiravaka 
et al., 2015)  
Madagascar 
2013-2014 
Pregnant 
women 
Cohort 
study 
Stool 66* 18.5% NI NI NI NI NI NI 36.0% NI 
E. Coli, 
Citrobacter 
freundii, K 
pneumoniae, 
Enterobacter 
cloaca., 
Morganella 
morganii. 
(Chereau et 
al., 2015) 
Mauritius 
2014 
Hosp 
Laboratory 
surveillance 
Blood 
culture, pus, 
burn, urine, 
swab, 
respiratory 
intravascular 
catheter 
301 NI NI NI NI 50.7% 33.2% NI 56.1% NI 
E. Coli, K. 
Pneumoniae 
(Issack, 
2016a) 
AMX: amoxicillin, AMC: amoxicillin + claviculanic acid, CAZ: ceftazidime, SXT: trimethoprim sulfamethoxazole, GEN: 689 
gentamicin, CIP: ciprofloxacin, NAL: nalidixic acid, CEF: cefotaxim; NI: not identified; *ESBL isolates only 690 
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